一种新型多草药配方PENN-DIABEX在高脂肪饮食中对链毒素诱导的糖尿病大鼠的影响
Mudassir Hassan1, Azhar Rasul1, Muhammad Ajmal Shah2,3
1Department of Zoology, Faculty of Life Sciences, Government College University Faisalabad, 38000 Faisalabad, Pakistan.
Saudi journal of biological sciences
|October 16, 2023
概括
这项研究表明,多草药配方 (PENN-DIABEX) 在糖尿病大鼠中显著改善了血糖和HbA1c. 该配方表现出比甲福明更好的疗效,没有观察到毒性.
科学领域:
- 药理学 药理学是指药理学的学科.
- 自然产品化学 自然产品化学
- 内分泌学 在内分泌学.
背景情况:
- 糖尿病是一种严重并发症的全球性健康问题.
- 有效的管理策略对于改善患者的治疗结果至关重要.
- 自然产品为糖尿病提供了潜在的治疗途径.
研究的目的:
- 为了评估多草药配方 (PENN-DIABEX) 的抗糖尿病作用.
- 评估PENN-DIABEX在链毒素诱导的糖尿病大鼠中的疗效.
- 为了比较PENN-DIABEX与甲福明,并评估其安全性.
主要方法:
- 在大鼠中,斯特佐托辛诱导的糖尿病模型.
- 用PENN-DIABEX在三种不同剂量和甲胺的管理.
- 对血液生物化学参数 (FBG,HbA1c,LFT,RFT,脂质概况) 的分析.
- 肝脏,脏和胰腺组织的组织病理学检查.
主要成果:
- 佩恩-迪亚贝克斯显著降低了禁食血糖 (FBG) 和糖化血红蛋白 (HbA1c) (P <0.01).
- 该配方改善了肝功能测试 (LFT),功能测试 (RFT) 和脂质资料.
- 组织病理学证实,肝脏,脏或胰腺没有代谢毒性.
- 与甲胺相比,PENN-DIABEX表现出优越的抗糖尿病作用.
结论:
- PENN-DIABEX具有显著的抗糖尿病特性.
- 多草药配方是安全的,并显示出作为替代糖尿病治疗的潜力.
- 对PENN-DIABEX的进一步研究可能会导致糖尿病管理的新型治疗策略.
相关概念视频
01:23Dipeptidyl Peptidase 4 Inhibitors
192
Dipeptidyl peptidase 4 (DPP-4) is a serine protease widely distributed in the body. It's involved in the inactivation of GLP-1 and GIP hormones, which are crucial for insulin regulation. DPP-4 inhibitors, such as sitagliptin (Januvia), saxagliptin (Onglyza), linagliptin (Tradjenta), alogliptin (Nesina), and vildagliptin (Galvus), help increase the proportion of active GLP-1, enhancing insulin secretion. These inhibitors work by competitively binding to DPP-4. This binding causes a...
192
01:26Oral Hypoglycemic Agents: Biguanides and Glitazones
212
Biguanides, particularly metformin (Glucophage), are insulin sensitizers that enhance glucose uptake, thereby reducing insulin resistance. Unlike sulfonylureas, metformin doesn't prompt insulin secretion, which helps to curb hypoglycemia risk. Metformin is beneficial in treating conditions like polycystic ovary syndrome due to its insulin-resistance reduction capability. The drug's primary action involves curtailing hepatic gluconeogenesis, a significant contributor to high blood...
212
01:24Glucagon-like Receptor Agonists
334
Incretins include glucagon-like peptide-1 (GLP-1) and glucose-dependent insulinotropic polypeptide (GIP), which stimulate insulin secretion post-meals. In type 2 diabetes, GIP's efficacy is reduced, making GLP-1 a viable drug target. GIP originates from preproGIP.
GLP-1, when administered in high doses intravenously, triggers insulin secretion, inhibits glucagon release, slows gastric emptying, reduces food intake, and restores normal insulin secretion. However, its rapid inactivation by...
GLP-1, when administered in high doses intravenously, triggers insulin secretion, inhibits glucagon release, slows gastric emptying, reduces food intake, and restores normal insulin secretion. However, its rapid inactivation by...
334